BridgeBio Pharma, Inc. Company Analysis & Research
BridgeBio exists to develop transformative medicines for genetic conditions, addressing the fact that millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. The company combines commercial momentum with a robust late-stage pipeline positioned to drive significant growth through 2026 and beyond.
BridgeBio is advancing its commercial strategy for Attruby and aims to double its patient reach by 2026, reflecting the effectiveness of its decentralized model in driving meaningful healthcare solutions. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.
Company Overview
Founded: 2015. Headquarters: Palo Alto, US. Revenue: $362.4M. Market Cap: $15.2B. Ticker: BBIO (NASDAQ).
Industry
Biotechnology - Genetic Medicine & Rare Diseases
Cyborg Score: 7/10 — Strong
De-risked pipeline with strong commercial execution on Attruby and multiple near-term approval catalysts position BridgeBio for substantial growth if execution succeeds despite ongoing cash burn challenges.
Recent positive Phase 3 PROPEL 3 results for infigratinib in achondroplasia demonstrated statistically significant gains with a favorable safety profile, and infigratinib achieved the highest reported absolute annualized height velocity in randomized achondroplasia trials, with FDA/European approvals expected in H2 2026. Attruby rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions and $362.4 million in full-year 2025 revenue demonstrates commercial traction. However, high cash burn and execution risks on multiple late-stage programs remain near-term pressures.
Key Strategic Insights for BridgeBio Pharma, Inc.
- February 2026 Phase 3 achondroplasia data breakthrough: infigratinib achieved record annualized height velocity gains with approvals expected H2 2026
- Attruby dominance in ATTR-CM with 6,629 patient prescriptions by year-end 2025 and $362.4 million 2025 revenue drives commercial base
- Three potential near-term NDA submissions: ADH1 (encaleret, H1 2026), LGMD2I/R9 (BBP-418, H1 2026), and Phase 2 data supporting hypochondroplasia indication
- Double patient reach goal by end of 2026 despite negative margins and high debt-to-equity ratio requiring successful launches
Recent Developments
- (February 2026) Positive Phase 3 PROPEL 3 topline data for infigratinib in achondroplasia with highest reported height velocity gains
- (January 2026) $550 million convertible senior notes offering completed; full-year 2025 Attruby revenue reached $362.4 million
- (January 2026) Strategic updates at J.P. Morgan Healthcare Conference including commercialization progress and 2026 milestones
Competitors & Competitive Landscape
- Amgen — Large pharma with rare disease focus and skeletal dysplasia research
- Alnylam Pharmaceuticals — RNA interference therapies for genetic diseases
- Arrowhead Pharmaceuticals — Genetic disease therapeutics
- Invitae — Genetic testing and counseling for rare conditions
BridgeBio competes in genetic disease treatment space with 93 identified competitors including IVERIC bio and other biotechnology firms. As a rare disease-focused biopharmaceutical company with Attruby as its commercial anchor, BridgeBio differentiates through targeted genetic medicine development and emerging clinical proof-of-concept across multiple rare indications. Success will depend on execution against larger pharma players and specialized rare disease developers.
More Company Research
Takween Advanced Industries Immix Biopharma, Inc. Cybin Inc. Yanbu Cement Company Hagar hf. I.B.I. Investment House Hangzhou Shunwang Technology Co., Ltd. Invincible Investment Corporation Fielmann Group AG Open House Group Co., Ltd. Westlake Corporation Amcor plc Ford Motor Company ADVFN Plc FingerTango Inc.Full Company Research Reports
Looking for a more in-depth analysis of BridgeBio Pharma, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.